Daily Anesthesiology Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
Today’s most impactful findings span three complementary areas: a reproducible survival model for severe acute limb ischemia, long-term clinical characterization of recreational tiletamine-zolazepam toxicity, and an individualized perioperative safety framework for GLP-1 receptor agonists. Together, these studies address major gaps in translational modeling, toxicologic recognition, and perioperative medication management.
Research Themes
- Methodological innovation in translational anesthesiology and vascular research
- Long-term neuropsychiatric and systemic consequences of anesthetic misuse
- Individualized perioperative medication safety and aspiration-risk management
Selected Articles
1. Endovascular dual internal-external iliac balloon occlusion creates a reproducible porcine survival model of unilateral acute hindlimb ischemia.
This experimental study developed a minimally invasive porcine survival model that reliably produces six hours of profound unilateral hindlimb ischemia by simultaneous internal and external iliac balloon occlusion. Absent distal flow, postoperative gait impairment, muscle necrosis, inflammatory injury, and loss of compound muscle action potentials validated the model across functional, electrophysiologic, and histologic domains.
Impact: The model solves a central technical problem in porcine acute limb ischemia research: collateral pelvic circulation often prevents complete ischemia. Its survival design enables longitudinal testing of ischemia-reperfusion therapies, functional recovery, and tissue injury with less confounding surgical trauma.
Clinical Implications: The model can accelerate preclinical evaluation of endovascular, pharmacologic, regenerative, and ischemia-reperfusion interventions for acute limb ischemia before human trials.
Key Findings
- Simultaneous internal and external iliac balloon occlusion produced consistent complete unilateral hindlimb ischemia for six hours without mortality or systemic morbidity.
- Angiography, Doppler ultrasonography, and pulse oximetry confirmed absent distal perfusion and lack of collateral reconstitution.
- At seven days, animals showed gait impairment, ischemic muscle necrosis and inflammation, and marked electrophysiologic nerve and muscle injury.
Methodological Strengths
- The study iteratively compared alternative occlusion strategies and directly addressed species-specific collateral anatomy.
- Model validity was assessed using blinded histology together with longitudinal functional and electrophysiologic outcomes.
Limitations
- The reported observation period was limited to seven days, so longer-term remodeling and recovery were not established.
- The model used healthy female Yorkshire pigs and may not fully reproduce human comorbidities, atherosclerosis, or variable clinical ischemia.
Future Directions: Future studies should extend follow-up, incorporate reperfusion and treatment arms, and test the model across animals with vascular risk factors. Multicenter replication and standardized outcome reporting would improve translational validity.
OBJECTIVE: Large-animal models are essential for studying acute limb ischemia (ALI), yet most existing porcine ALI models are nonsurvival designs intended for short-term physiologic or metabolic investigation. In contrast, current survival models predominantly replicate chronic limb ischemia by surgically ligating the external iliac artery (EIA) or common femoral artery (CFA), an approach that does not generate a complete acute ischemic insult. To address this limitation, we developed a reproducible, minimally invasive survival model of unilateral hindlimb ALI using simultaneous balloon occlusion of the ipsilateral internal artery and EIA.
2. Neuropsychiatric and multisystem toxicity following recreational inhalation of tiletamine-zolazepam (Zoletil 50): a retrospective case series with two-year prospective follow-up.
In 36 patients with recreational Zoletil 50 inhalation, tremor occurred in all patients, cerebellar ataxia in 83%, and visual disturbance in 56%; three patients died. Among discharged patients, 59% relapsed, and persistent memory, visual, or parkinsonian deficits remained in a substantial proportion at two years, highlighting clinically important chronic toxicity that routine toxicology screens may miss.
Impact: This is one of the few reports combining acute clinical toxicity with two-year outcomes for a veterinary anesthetic increasingly misused by humans. The high relapse rate, deaths, and persistent neurologic deficits provide actionable information for emergency, addiction, neurology, and anesthesiology services.
Clinical Implications: Clinicians should consider tiletamine-zolazepam exposure in patients with unexplained tremor, ataxia, hallucinations, or visual disturbance, recognizing that standard toxicology panels may not detect it. Management should include cardiorespiratory monitoring, neurologic assessment, relapse prevention, and extended follow-up.
Key Findings
- All 36 patients had postural tremor; cerebellar ataxia occurred in 30 patients and visual disturbance in 20.
- Two patients died during hospitalization, and a third died during follow-up after a fifth relapse.
- Of 34 discharged patients, 20 relapsed, while 11 of 33 survivors had persistent neurologic deficits at two years.
Methodological Strengths
- The study captured a broad spectrum of neurologic, psychiatric, laboratory, and systemic outcomes.
- Two-year follow-up allowed assessment of relapse timing and persistent deficits rather than only acute toxicity.
Limitations
- The retrospective case-series design without an exposed control group limits causal inference and may be affected by referral and selection bias.
- Exposure dose, route details, co-intoxicants, and standardized neuropsychological assessments were not fully controlled or uniformly available.
Future Directions: Prospective multicenter surveillance should define dose-response relationships, co-exposure effects, mechanisms of persistent neurotoxicity, and evidence-based detoxification and relapse-prevention strategies. Development of targeted toxicology assays is also warranted.
BACKGROUND: Tiletamine-zolazepam (Zoletil) is a veterinary anesthetic, which is increasingly being abused by humans. However, the chronic neurotoxicity of this compound in humans and its long-term clinical outcomes have rarely been reported. OBJECTIVE: To characterize the neurological and systemic injury following recreational Zoletil 50 inhalation, including relapse behavior and persistent deficits. METHODS: We performed a retrospective case series of patients presenting to our institution with Zoletil 50 toxicity. We analyzed the clinical features, laboratory results, and neuroimaging findings, and assessed long-term outcomes and relapse rates during a two-year observation period.
3. Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.
This review proposes a pharmacist-led pathway for perioperative management of GLP-1 receptor agonists that integrates medication verification, last-dose timing, gastrointestinal symptoms, treatment escalation, motility disorders, procedure urgency, glycemic consequences, and postoperative restart. It emphasizes that evidence for aspiration pneumonia risk is inconsistent and that routine discontinuation may create metabolic harms, supporting individualized multidisciplinary assessment instead.
Impact: GLP-1 receptor agonist use is expanding rapidly, while perioperative guidance remains heterogeneous and largely based on limited observational evidence. The framework translates evolving evidence into an implementable medication-safety workflow and explicitly balances aspiration concerns against hyperglycemia and treatment interruption.
Clinical Implications: Perioperative teams should avoid relying solely on routine GLP-1 receptor agonist cessation. Instead, they should document the indication, treatment phase, dose escalation, last dose, gastrointestinal symptoms, comorbid motility disorders, aspiration risk, glycemic risk, and postoperative restart plan; selective gastric ultrasonography may support decision-making in higher-risk patients.
Key Findings
- GLP-1 receptor agonists can delay gastric emptying and increase residual gastric contents despite standard fasting.
- Available perioperative outcome studies have not consistently demonstrated increased aspiration pneumonia risk and are limited by retrospective designs and low event rates.
- A pharmacist-led pathway should combine medication verification, symptom screening, risk phenotyping, multidisciplinary escalation, day-of-surgery reassessment, and postoperative restart planning.
Methodological Strengths
- The review integrates pharmacologic mechanisms, perioperative outcome evidence, professional guidance, gastric ultrasonography, and medication-safety considerations beyond aspiration.
- It provides a concrete multidisciplinary implementation pathway rather than only a narrative discussion of risk.
Limitations
- The proposed pathway is not prospectively validated in real-world perioperative practice.
- Much of the underlying clinical evidence is retrospective, with heterogeneous definitions of residual gastric contents and few aspiration-related events.
Future Directions: Prospective implementation studies should evaluate whether individualized pharmacist-anesthesia pathways reduce cancellations, aspiration events, dysglycemia, and medication-related errors while preserving the therapeutic benefits of GLP-1 receptor agonists. Standardized gastric ultrasound protocols and outcome definitions are needed.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes, obesity, and broader cardiometabolic, cardiorenal, and metabolic liver disease indications, creating new challenges for perioperative medication safety. This review summarizes current evidence on GLP-1RA-associated delayed gastric emptying and proposes a structured pharmacist-led framework for individualized perioperative risk management. GLP-1RAs may increase the likelihood of residual gastric contents during anesthesia or procedural sedation despite adherence to standard fasting recommendations.